Assuming adamas is required, the following results were found.

  • 10 Worst-Performing Stocks of 2019 - Motley Fool

    focusing on its fixed-price home services business, which could move ANGI Homeservices out of the penalty box in 2020. 4. Adamas Pharmaceutical -- down 56.6% YTD Adamas Pharmaceutical (NASDAQ:ADMS) shares have been feeling the pain largely because of...

    https://mschristian.org/index.php/blog/10-worst-performing-stocks-of-2019-motley-fool
  • Dementia Life Expectancy; Teens and Opioids; Duchenne Test for Newborns

    FDA approval. A phase III study of amantadine (ADS-5102) for MS patients with walking impairment met its primary endpoint, Adamas reported. Sleep fragmentation predicted migraine risk a day later. (Neurology) The FDA broadened the existing label for...

    https://mschristian.org/index.php/blog/dementia-life-expectancy-teens-and-opioids-duchenne-test-for-newborns

Results 1 - 2 of 2
 
 

Follow Us on Twitter

Follow Us On Twitter - Image